Cargando…
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report
Autores principales: | Schüller, Hannah, Klein, Franziska, Lübbert, Michael, Prager, Eric Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652905/ https://www.ncbi.nlm.nih.gov/pubmed/33170342 http://dx.doi.org/10.1007/s00277-020-04318-6 |
Ejemplares similares
-
The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009) -
Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report
por: Quinquenel, Anne, et al.
Publicado: (2017) -
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
por: de Castro, Carlos, et al.
Publicado: (2020) -
The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
por: Kim, Jin Seok, et al.
Publicado: (2010) -
Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report: Erratum
Publicado: (2017)